Egrifta (tesamorelin) Disease Interactions
There are 3 disease interactions with Egrifta (tesamorelin):
Tesamorelin (applies to Egrifta) pituitary tumor
Major Potential Hazard, Moderate plausibility. Applicable conditions: Head Injury, Panhypopituitarism
The use of tesamorelin is contraindicated in patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma and in patients with active malignancy.
Tesamorelin (applies to Egrifta) diabetes
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus
The use of tesamorelin can result in glucose intolerance. Tesamorelin increases insulin-like growth factor-1 (IGF-1). It is recommended to evaluate glucose status prior to initiation of therapy and to monitor periodically during treatment. Therapy discontinuation may be considered in patients that do not show a clear efficacy response and develop glucose intolerance or diabetes. Diabetes patients should be monitored for potential development or worsening of retinopathy. Care should be exercised when using this agent in patients with diabetes.
Tesamorelin (applies to Egrifta) fluid retention
Moderate Potential Hazard, Moderate plausibility.
The use of tesamorelin may cause fluid retention related to the induction of growth hormone secretion. This manifests as increased tissue turgor and musculoskeletal discomfort resulting in adverse reactions (e.g. edema, arthralgia, and carpal tunnel syndrome) which are either transient or resolve with discontinuation of treatment. Care should be exercised when using tesamorelin in patients at risks for fluid retention.
Egrifta (tesamorelin) drug interactions
There are 45 drug interactions with Egrifta (tesamorelin)
More about Egrifta (tesamorelin)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- En Español
- 13 Reviews
- Drug class: growth hormones
- FDA Approval History
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.